Vaxcyte, Inc. (PCVX) Stock

Vaxcyte, Inc. (PCVX) is a Healthcare stock trading at $61.33 (as of 2026-08-20), with a market capitalization of $8.86B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Vaxcyte, Inc. is a clinical-stage biotechnology company developing protein-based vaccine candidates to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-24 for invasive pneumococcal disease and pneumonia and other programs for emerging pneumococcal strains and additional bacterial targets.

Understand Vaxcyte, Inc.: how it makes money

Vaxcyte, Inc. develops protein vaccines to prevent or treat bacterial infectious diseases, including its 24-valent pneumococcal conjugate vaccine VAX-24, and it would need successful clinical development and later commercialization or licensing to generate meaningful revenue.

Because Vaxcyte is a clinical stage vaccine developer, the path to potential future profit is structurally tied to clinical execution (enrollment and study coverage for its vaccine candidates), rather than current product sales.

Business quality (Weak): Clear pipeline focus and trackable clinical execution metrics, but the latest quarter shows no revenue and a large operating loss, meaning progress must translate into successful trial outcomes before any commercial earnings power is visible.

Bull case

  • Lead candidate is defined, and specific study progress is measurable: VAX-24 is in Phase 1/2 clinical trials, and the company provides a VAX-24 enrollment KPI (802 count).
  • Program includes additional pneumococcal coverage and study performance metrics: Operational KPIs include VAX-31 coverage metrics for invasive pneumococcal disease and acute otitis media (both reported as percent), which track how broadly the approach targets disease.

Bear case

  • No current revenue, large operating losses, and reliance on ongoing clinical milestones: For the period ended 2026-03-31, revenue is shown as 0.0B and operating margin is -1299.7, consistent with continued R and D before commercialization.
  • Clinical execution risk is central: Operational tracking emphasizes enrollment and coverage across studies, so slower enrollment, lower coverage performance, or trial disruptions could delay progress for the vaccine candidates.
Valuation — source: SEC EDGAR (first-party)
Price$61.33
Market Cap$8.86B
Price / Book2.96
Price / Sales73.87
FCF Yield-13.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$119.72M
Net Margin-640.4%
Revenue Growth (YoY)8.8%
EPS Growth (YoY)48.2%
FCF Growth (YoY)40.9%
Financial Health — source: SEC EDGAR
Altman Z-Score15.28 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJupiter Topco LLC ($1.04B)
Institutional Holders Tracked10
Congressional Trades (recent)8
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOGrant E. Pickering
Employees414
CountryUS
IPO Date2020-06-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Apogee Therapeutics, Inc. (APGE)
  • Kymera Therapeutics, Inc. (KYMR)
  • Krystal Biotech, Inc. (KRYS)
  • Immunovant, Inc. (IMVT)
  • Twist Bioscience Corporation (TWST)
  • ImmunityBio, Inc. (IBRX)
  • CG Oncology, Inc. Common stock (CGON)
  • Scholar Rock Holding Corporation (SRRK)
PCVX earnings history · PCVX institutional & insider holders · PCVX KPIs & operating metrics · PCVX financials · PCVX investor presentations & press releases · PCVX SEC filings · PCVX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.